A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \<70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start emicizumab treatment as part of this study.

NCT Number	NCT05181618
Lead Sponsor	Hoffmann-La Roche
Conditions	Severe Hemophilia A, Moderate Hemophilia A
Enrollment	136 participants
Start Date	2022-06-20
Primary Completion	2026-12-04 (estimated)
Study Completion	2027-05-21 (estimated)
Updated on ClinicalTrials.gov	2026-04-27